polycythemia vera; rusfaertide; hepcidin mimetic

Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for men vs women. https://www.ajmc.com/view/understanding-hematocrit-thresholds-in-polycythemia-vera-treatment In early March, The American Journal of Managed Care® spoke with...

Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to overproduction of various blood cells. Summary: Managing Polycythemia Vera to Reduce Risks and Improve Lives Polycythemia vera (PV) is a chronic myeloproliferative neoplasm-a type...

*rusfertide, a novel hepcidin mimetic Elevated hematocrit is a hallmark of polycythemia vera (PV), and it is associated with higher rates of death. Whilst it is essential to maintain hematocrit levels below 45% to decrease the risk of thrombotic and cardiovascular events, current standards...